Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-11-18
2004-09-28
Trinh, Ba K. (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C549S214000, C549S511000
Reexamination Certificate
active
06797833
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention is directed to novel taxanes which have utility as antileukemia and antitumor agents.
The taxane family of terpenes, of which taxol is a member, has attracted considerable interest in both the biological and chemical arts. Taxol is a promising cancer chemotherapeutic agent with a broad spectrum of antileukemic and tumor-inhibiting activity. Taxol has a 2′R, 3′S configuration and the following structural formula:
wherein Ac is acetyl. Because of this promising activity, taxol is currently undergoing clinical trials in both France and the United States.
Colin et al. reported in U.S. Pat. No. 4,814,470 that taxol derivatives having structural formula (2) below, have an activity significantly greater than that of taxol (1).
R′ represents hydrogen or acetyl and one of R″ and R′″ represents hydroxy and the other represents tert-butoxy- carbonylamino and their stereoisomeric forms, and mixtures thereof. The compound of formula (2) in which R′ is hydrogen, R″ is hydroxy, R′″ is tert-butoxycarbonylamino having the 2′R, 3′S configuration is commonly referred to as taxotere.
Although taxol and taxotere are promising chemotherapeutic agents, they are not universally effective. Accordingly, a need remains for additional chemotherapeutic agents.
SUMMARY OF THE INVENTION
Among the objects of the present invention, therefore, is the provision of novel taxane derivatives which are valuable antileukemia and antitumor agents.
Briefly, therefore, the present invention is directed to C9 taxane derivatives. In a preferred embodiment, the taxane derivative has a tricyclic or tetracyclic core and corresponds to the formula:
wherein
X
1
is —OX
6
, —SX
7
, or —NX
8
X
9
;
X
2
is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;
X
3
and X
4
are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;
X
5
is —COX
10
, —COOX
10
, —COSX
10
, —CONX
8
X
10
, or —SO
2
X
11
;
X
6
is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxy protecting group, or a functional group which increases the water solubility of the taxane derivative;
X
7
is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or sulfhydryl protecting group;
X
8
is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl;
X
9
is an amino protecting group;
X
10
is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterosubstituted alkyl, alkenyl, alkynyl, aryl or heteroaryl;
X
11
is alkyl, alkenyl, alkynyl, aryl, heteroaryl, —OX
10
, or —NX
8
X
14
;
X
14
is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;
R
1
is hydrogen, hydroxy, protected hydroxy or together with R
14
forms a carbonate;
R
2
is hydrogen, hydroxy, —OCOR
31
, or together with R
2a
forms an oxo;
R
2a
is hydrogen or together with R
2
forms an oxo;
R
4
is hydrogen, together with R
4a
forms an oxo, oxirane or methylene, or together with R
5a
and the carbon atoms to which they are attached form an oxetane ring;
R
4a
is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyano, hydroxy, —OCOR
30
, or together with R
4
forms an oxo, oxirane or methylene;
R
5
is hydrogen or together with R
5a
forms an oxo,
R
5a
is hydrogen, hydroxy, protected hydroxy, acyloxy, together with R
5
forms an oxo, or together with R
4
and the carbon atoms to which they are attached form an oxetane ring;
R
6
is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl, hydroxy, protected hydroxy or together with R
6a
forms an oxo;
R
6a
is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl, hydroxy, protected hydroxy or together with R
6
forms an oxo;
R
7
is hydrogen or together with R
7a
forms an oxo,
R
7a
is hydrogen, halogen, protected hydroxy, —OR
28
, or together with R
7
forms an oxo;
R
9
is hydrogen;
R
9a
is hydrogen, hydroxy, protected hydroxy, or acyloxy;
R
10
is hydrogen or together with R
10a
forms an oxo,
R
10a
is hydrogen, —OCOR
29
, hydroxy, or protected hydroxy, or together with R
10
forms an oxo;
R
14
is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl, hydroxy, protected hydroxy or together with R
1
forms a carbonate;
R
14a
is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl;
R
28
is hydrogen, acyl, hydroxy protecting group or a functional group which increases the solubility of the taxane derivative; and
R
29
, R
30
and R
31
are independently hydrogen, alkyl, alkenyl, alkynyl, monocyclic aryl or monocyclic heteroaryl.
Other objects and features of this invention will be in part apparent and in part pointed out hereinafter.
REFERENCES:
patent: 4814470 (1989-03-01), Colin et al.
patent: 4876399 (1989-10-01), Holton et al.
patent: 4921974 (1990-05-01), Duggan
patent: 4924011 (1990-05-01), Denis et al.
patent: 4924012 (1990-05-01), Colin et al.
patent: 5015744 (1991-05-01), Holton
patent: 5059699 (1991-10-01), Kingston et al.
patent: 5136060 (1992-08-01), Holton
patent: 5175315 (1992-12-01), Holton
patent: 5227400 (1993-07-01), Holton et al.
patent: 5229526 (1993-07-01), Holton
patent: 5243045 (1993-09-01), Holton et al.
patent: 5250683 (1993-10-01), Holton et al.
patent: 5254703 (1993-10-01), Holton
patent: 5264591 (1993-11-01), Bombardelli et al.
patent: 5274124 (1993-12-01), Holton
patent: 5283253 (1994-02-01), Holton et al.
patent: 5284864 (1994-02-01), Holton et al.
patent: 5284865 (1994-02-01), Holton et al.
patent: 5336785 (1994-08-01), Holton
patent: 5338872 (1994-08-01), Holton et al.
patent: 5350866 (1994-09-01), Holton et al.
patent: 5352806 (1994-10-01), Gunawardana et al.
patent: 5384399 (1995-01-01), Holton
patent: 5399726 (1995-03-01), Holton et al.
patent: 5405972 (1995-04-01), Holton et al.
patent: 5430160 (1995-07-01), Holton
patent: 5440056 (1995-08-01), Klein et al.
patent: 5466834 (1995-11-01), Holton
patent: 5489601 (1996-02-01), Holton et al.
patent: 5532363 (1996-07-01), Holton
patent: 5539103 (1996-07-01), Holton
patent: 5574156 (1996-11-01), Holton
patent: 5723634 (1998-03-01), Holton
patent: 5728725 (1998-03-01), Holton et al.
patent: 6011056 (2000-01-01), Holton et al.
patent: 0400971 (1990-12-01), None
patent: 0428376 (1991-05-01), None
patent: 0534707 (1993-03-01), None
patent: 0534708 (1993-03-01), None
patent: 0534709 (1993-03-01), None
patent: 919224 (1993-11-01), None
patent: WO 93/02065 (1993-02-01), None
patent: WO 94/08984 (1994-04-01), None
Borman “New Family of Taxol, Taxotere Analogs Developed” Chem. & Engineering News, Science/Technology (Apr. 12, 1993) pp. 26-27.
Chen et al. “Taxol Structure-Activity Relationships: Synthesis and Biological Evaluation of 2-Deoxytaxol” Tetrahedron Letters, vol. 34, No. 20 (1993) pp. 2305-2306.
Denis et al. “A Highly Efficient, Practical Approach to Natural Taxol”, J. Am Chem. Soc. vol. 110, No. 17 (1988) pp. 5917-5919.
Farina et al. “The Chemistry of Taxanes: Unexpected Rearrangement of Baccatin III During Chemoselective Debenzoylation with Bu3SnOMe/LiCl” Tetrahedron Letters, vol. 33, No. 28 (1992) pp. 3979-3982.
Holton et al., “A Synthesis of Taxusin”, Journal of American Chemical Society, vol. 110 (1988) pp. 6558-6560.
Kingston et al. “The Taxane Diterpenoids” Progress in the Chemistry of Organic Natural Products, Wein, NY Springer-Verlag, 1993.
Klein “Synthesis of 9-Dihydrotaxol: A Novel Bioactive Taxane”, Tetrahedron Letters, vol. 34, No. 13 (1993) pp 2047-2050.
Miller et al. “Antileukemic Alkaloids from Taxus Wallichiana Zucc.”, Journal of Organic Chemistry, vol. 46, No. 7, (1981) pp. 1469-1474.
Ojima et al. “New and Efficient Approaches to the Semisynthesis of Taxol and its C-13 Side-Chain Analogs by Means of &bgr;-Lactam Synthon Method” Tetrahedron, vol. 48, No. 34 (1992) pp. 6985-7012.
Samaranayake et al. “Modified Taxols. 5.1 Reaction of Taxol with Electrophilic Reagents and Preparation of a Rearranged Taxol Derivative with Tubulin Assembly Activity” Journal of Organic Chemistry, vol. 56, No. 7 (1991) pp. 5114-5119.
Senilh et al., “Hemisynthese de nouveaux analogues du taxol. Etude de leur interaction avec la tubuline”, C.R. Acad. Sc. Paris, Serie II
Chai Ki-byung
Holton Robert A.
Suzuki Yukio
Florida State University
Senniger Powers Leavitt & Roedel
Trinh Ba K.
LandOfFree
C9 hydrido and acyloxy metal alkoxides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C9 hydrido and acyloxy metal alkoxides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C9 hydrido and acyloxy metal alkoxides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3207921